Price T Rowe Associates Inc Sage Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 450,637 shares of SAGE stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

450,637

Previous 512,837 12.13%

Holding current value

$2.53 Million

Previous $5.57 Million 41.58%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $436,644 - $813,576	-62,200 Reduced 12.13%	450,637 $3.25 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $3.16 Million - $5.35 Million	-299,097 Reduced 36.84%	512,837 $5.57 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $6.22 Million - $9 Million	333,805 Added 69.81%	811,934 $15.2 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $1.78 Million - $2.32 Million	-104,143 Reduced 17.89%	478,129 $10.4 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $8.34 Million - $24.4 Million	-497,881 Reduced 46.09%	582,272 $12 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $33.7 Million - $49.3 Million	-828,238 Reduced 43.4%	1,080,153 $50.8 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $412,541 - $515,483	11,069 Added 0.58%	1,908,391 $80.1 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $7.83 Million - $10.6 Million	-243,089 Reduced 11.36%	1,897,322 $72.4 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $2.03 Million - $2.72 Million	62,877 Added 3.03%	2,140,411 $83.8 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $2.23 Million - $3.08 Million	-80,970 Reduced 3.75%	2,077,534 $67.1 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $22.8 Million - $33.9 Million	741,982 Added 52.38%	2,158,504 $71.4 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $356,998 - $453,810	9,633 Added 0.68%	1,416,522 $60.3 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $6.63 Million - $9.45 Million	-164,664 Reduced 10.48%	1,406,889 $62.3 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $45.8 Million - $66.2 Million	-835,294 Reduced 34.7%	1,571,553 $89.3 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $3.5 Million - $4.79 Million	49,505 Added 2.1%	2,406,847 $180 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $138 Million - $210 Million	2,357,342 New	2,357,342 $204 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $333M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Sage Therapeutics, Inc. Transaction History